Results 251 to 260 of about 9,628,828 (350)

Sex-dependent endocrine and cellular effects of the GnRH antagonist degarelix in rabbits and cell models. [PDF]

open access: yesAm J Transl Res
Zhao M   +11 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy